New treatment could spare early-stage rectal cancer patients life-altering side effects

December 10, 2020

A new and less invasive treatment developed by Cancer Research UK researchers is safer than standard major surgery for early-stage rectal cancer, giving patients a better quality of life with fewer life-altering side effects, results from a pilot study show.

Results from the TREC trial show that a combination of local keyhole surgery and radiotherapy, rather than major surgery that removes the whole rectum, prevents debilitating side effects, such as diarrhoea, or the need for a permanent colostomy bag.

Patients reported a better quality of life with the new treatment, with less impact on their family and social life, and felt more positive about their body image and the way their bowels work.

The findings are published in The Lancet Gastroenterology & Hepatology today (Thursday)*, and a clinical trial is now open to eligible patients who wish to receive this new treatment**.

Every year, 11,500 people in the UK are diagnosed with a tumour located in the rectum,*** the last part of the intestine which connects to the anus. Standard treatment is a major operation to remove the whole rectum, even if the cancer is early stage. About 25% of these major surgeries are done on small, early-stage tumours, and while it is effective, the operation can lead to long-term side-effects that seriously impacts quality of life for survivors.

43% of rectal cancers are caught at an early stage (stage 1 and 2) and doctors need better, less invasive treatments for these tumours.

Mr Simon Bach and his team at the University of Birmingham, along with collaborators at the University of Leeds, have developed a new treatment approach called 'organ preservation' for early-stage rectal cancer that uses radiotherapy followed by local keyhole surgery 8-10 weeks later to remove only the part of the rectum affected by cancer.

Mr Simon Bach, lead researcher, says: "We took a lot of inspiration from progress against breast cancer. In the early 90s, most people with breast cancer would have a mastectomy, where the whole breast is removed, as the first part of their treatment. But now, due to awareness campaigns, the breast screening programme and new treatments, mastectomy is much rarer. We wanted to test a similar approach for our rectal cancer patients."

To test whether organ preservation treatment could be a suitable alternative to major surgery for early-stage rectal cancer, 123 patients were enrolled in the TREC trial****.

Doctors gave the new treatment to 61 patients for whom the major surgery would have been considered unsafe.

In addition, 55 patients were randomised to two treatment approaches; 28 received major surgery and 27 received the new organ preserving treatment. 70% (19/27) of these were treated successfully, meaning their tumour was removed while preserving the rest of their rectum and their cancer did not return during the 3- to 5-year follow-up period. People who received the new treatment also reported fewer side-effects***** than people who had major surgery.

The analysis of patient-reported quality of life for 3 years after treatment, by Cancer Research UK clinical trial fellow Dr Alexandra Gilbert, found that people who received the new treatment fared better. They reported less diarrhoea, less embarrassment about their bowel functions, felt more satisfied with their body image, and felt like their treatment interfered less with their family life and social life compared with those who received major surgery.

Similar results were also seen in the 61 patients for whom the standard surgery would have been considered unsafe, showing that the new treatment could be a safe and effective option.

Co-author Dr Alexandra Gilbert, from the University of Leeds and Leeds Teaching Hospitals NHS Trust, said: "When talking about cancer treatment, the focus is rarely on how severe the effects can be for patients. But we studied this in detail and found that our organ preservation approach made a significant difference to people's quality of life. One of the most striking benefits was avoiding the need for a stoma bag, which we know is really important to our patients."

Mr Simon Bach and his team are now running an international, larger-scale version of their study, called STAR TREC******, across the UK, Netherlands and Denmark. The trial will help decide whether the new treatment should become the new standard treatment for early rectal cancer. This follow-up trial is currently open for recruitment, and importantly, patients may decide if they prefer to receive organ preservation.

The researchers are encouraging people who have been diagnosed with an early-stage rectal tumour to discuss their options with their surgeon should they wish to consider joining the ongoing trial.

Michelle Mitchell, chief executive of Cancer Research UK, said: "When people with cancer finish their cancer therapy, it's not the end of the ordeal. The physical and emotional strain from the effects of treatment can last for years afterwards, or even a lifetime.

"Patients are at the heart of what we do, and that's why results from trials like TREC are such good news. If we can find less intensive treatments with fewer side-effects, patients feel stronger and more confident, and they are in a better place to socialise, enjoy time with their friends and family, and live life to the fullest."

Martin Ledwick, Cancer Research UK's head information nurse, said: "This new treatment could be life-changing for people diagnosed with early-stage cancer. Diagnosing bowel cancer earlier means treatments are far more likely to work, so we encourage eligible people to consider taking part in bowel cancer screening when they receive their testing kit, and for anyone who notices any changes to their body to tell their GP about it."
Notes to editor:

* Bach, S. P., Gilbert, A. G., et. al. 2020. Transanal endoscopic microsurgery (TEM) and Radiotherapy in Early rectal Cancer (TREC): randomized, feasibility study comparing radical surgery versus short course radiotherapy and TEM. Lancet Gastroenterology & Hepatology. DOI: 10.1016/ S2468-1253(20)30390-3

Link (live after embargo lift):

** STAR TREC (Can we Save the rectum by Watchful waiting or TransAnal microsurgery following (chemo)Radiotherapy versus Total mesorectal excision for early Rectal Cancer?) is a Phase 2/3 trial for people with early-stage cancer of the rectum, open for recruitment until 2024. For more information on who can join the trial, please visit:

*** Based on the average annual number of new cases of rectal cancer (ICD10 C20) diagnosed in the UK between 2015 and 2017.

**** The TREC study was led from the Queen Elizabeth Hospital in Birmingham, the Birmingham Clinical Trials Unit and the Cancer Research UK Clinical Trials Unit (CRCTU) based at the University of Birmingham with another 20 centres around the country. The CRCTU runs small Phase I trials to large multi-centred international randomised trials and has a mission to translate cutting edge research into clinical practice.

***** Among the 55 randomised patients, serious side effects were only half as common in the new treatment group (15%; 4/27 patients) compared to the standard surgery group (39%; 11/28 patients). And the side-effects from the new treatment were also less severe. Patients most commonly reported bleeding or pain after the keyhole surgery whereas the side-effects in the radical surgery group included surgical complications like leaks of bowel contents at the site of surgery, kidney injury, cardiac arrest and pneumonia.

****** The STAR TREC study will refine the organ preservation treatment and will use a smaller and more precise radiotherapy field to further reduce side-effects. Two different types of organ preservation treatments will be used to determine which is better at treating early-stage rectal cancer: either a short course of high-dose radiotherapy, or a longer course of low-dose radiotherapy with chemotherapy. Patients who choose the organ preservation route are randomly assigned to either of these. In some cases, radiotherapy or chemoradiotherapy alone may be enough to treat the cancer.

Cancer Research UK

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to